(1) European Society Paediatric Gastroenterology, Hepatology and Nutrition (ESPGHAN) guidelines have allowed a CeD diagnosis in pediatric patients without histological investigation if their immunoglobulin A anti-tissue transglutaminase antibody (tTG-IgA) levels are at least 10 times the upper normal limit, and they have classical symptoms, positive immunoglobulin A anti-endomysial antibodies (EMA-IgA), and a predisposing human leukocyte antigen (HLA) serotype DQ-2 or DQ-8 [4]. Here, CD79A is linked to cranioectodermal dysplasia.